Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms KPMW 135, KPMW135 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization |
Inactive Organization ![]() |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | ![]() | 07 Dec 2020 |